<DOC>
	<DOC>NCT00711165</DOC>
	<brief_summary>A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.</brief_summary>
	<brief_title>Mometasone and Markers of Airway Inflammation</brief_title>
	<detailed_description>Patients with asthma and not treated with anti-inflammatory medications were studied. This was a parallel, randomized, placebo-controlled study to investigate the effects of Asmanex on markers of airway inflammation including exhaled nitric oxide, airway reactivity, FEV1 and nitrates/nitrites and pH in exhaled breath condensate.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Asthma nonsmoker FEV1 of at least 60% predicted Pregnancy or lactation Corticosteroid use in past 30 days</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Exhaled Breath Condensate</keyword>
	<keyword>Methacholine Challenge</keyword>
</DOC>